Pharmaceuticals
NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation. SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ -- NovaGo Therapeutics AG, a ...
2026-09-02 18:00
2767
Despite nationwide basic stroke treatment coverage, delays accessing advanced stroke care in Vietnam vary by region, new report finds
Patients in Vietnam's Southwest region and Mekong Delta can travel up to ten hours for advanced stroke care; Vietnamese experts point to a public-private model in Can Tho as a way to close that gap. HO CHI MINH CITY, Vietnam, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach a...
2026-09-02 15:00
4756
Workforce shortages and limited public hospital capacity remain major barriers to stroke care in the Philippines, new report finds
Filipino experts call for equipping more public hospitals with advanced imaging technology, stronger EMS infrastructure and greater investment in specialist training to close these gaps MANILA, Philippines, Sept. 2, 2026 /PRNewswire/ -- Workforce shortages and limited public hospital capacity re...
2026-09-02 15:00
5112
Delays before patients reach stroke centres remain a major barrier to timely treatment in Malaysia, new report finds
Malaysia experts call for better public awareness of stroke symptoms, standardised hospital imaging protocols and expanded access to specialist care beyond major urban centres KUALA LUMPUR, Malaysia, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach stroke centres remain a maj...
2026-09-02 15:00
5214
Delays Before Patients Reach Stroke Centers Still Hinder Timely Treatment Across Southeast Asia, Siemens Healthineers Report Finds
New research commissioned by Siemens Healthineers shows transportation delays, slow reporting processes as leading barriers to timely stroke diagnosis. * Stronger referral networks, public awareness, AI-enabled diagnostics, coordinated care are key to strengthening stroke system readiness acros...
2026-09-02 15:00
5140
HEC Group Enters Strategic Partnerships in Macau to Advance the Internationalization of Cordyceps Sinensis
MACAU, Sept. 2, 2026 /PRNewswire/ -- HEC Group has entered into strategic partnerships with MCCY Science & Greater Health Manufactory (operating regionally as Seed Scientific Research International Limited) and Longtai Health to strengthen the production, commercialization and international deve...
2026-09-02 10:00
2411
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
* The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. * Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement an...
2026-09-02 09:27
2089
Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
Haier Biomedical Accelerates Its Transformation into an Intelligent
Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026
SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical
2026-09-01 22:50
3310
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...
2026-09-01 19:30
2186
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...
2026-09-01 19:15
2434
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of lega...
2026-09-01 19:00
2487
JIANGXI BIO Announced 2026 Interim Results
Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights Key Financial Indicators * Revenue amounted to RMB83.3 mn; gross profit amounted to RMB60.3 mn, ...
2026-09-01 14:44
6304
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET
SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited
2026-09-01 07:23
5187
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
The next generation in skin resurfacing technology is available to Australian health care practitioners beginning 1 September 2026 LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics busines...
2026-09-01 06:00
2630
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...
2026-08-31 20:38
4841
SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring
MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with...
2026-08-31 12:17
1404
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
* Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant and have received at lea...
2026-08-31 09:00
2433
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg) over 72...
2026-08-30 18:15
2964
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the ...
2026-08-28 19:30
3209
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
* Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization * DUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises...
2026-08-28 12:20
2326
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 292 media titles]
2026-09-24 10:30
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 279 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 277 media titles]
2026-09-21 08:00Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 275 media titles]
2026-09-25 14:45
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
12228
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
10943
Dreame Technology Opens New Flagship Store at Suntec City, Expanding Smart Living Experience in Singapore
2026-09-25 18:33
9870
